Sonoma Biotherapeutics is focused on developing innovative living cell therapies aimed at restoring balance to the immune system, particularly in the context of autoimmune and inflammatory diseases. Their approach leverages the body's own immune response regulators, specifically regulatory T cells (T regs), to counteract an overactive immune response. The company is pioneering advancements in T reg biology and cell therapy, building on extensive research to create therapies that can target specific tissues and provide long-lasting therapeutic effects. Their lead product candidate, SBT-77-7101, is an autologous T reg cell therapy designed to treat conditions such as rheumatoid arthritis and hidradenitis suppurativa by dampening inflammation and restoring immune balance.

In addition to T reg therapies, Sonoma Biotherapeutics is also developing SBT-11-5301, a biologic therapy that modulates effector T cells (T effs) to address the imbalance often seen in autoimmune diseases. This dual approach of targeting both T regs and T effs aims to create a comprehensive treatment strategy that can induce durable immune system balance. The company is actively conducting clinical trials for its product candidates and has established partnerships, such as with Regeneron, to further advance engineered T reg therapeutics for various inflammatory bowel diseases. Through these efforts, Sonoma Biotherapeutics seeks to transform the treatment landscape for autoimmune conditions and improve patient outcomes.

United States

Sonoma Biotherapeutics is developing engineered regulatory T cell (Treg) therapies to treat serious autoimmune and inflammatory diseases driven by an imbalanced immune system. Founded by pioneers in Treg biology and cell therapy, the company is employing proprietary platform technologies and approaches to develop a new generation of targeted Treg cell therapies designed to induce durable immune tolerance to treat and prevent autoimmune and inflammatory diseases. Sonoma Biotherapeutics is based in South San Francisco and Seattle.

Sonoma Biotherapeutics

Company Details